Brain Tumor End Points Workshop January 20, 2006 Bethesda North Marriott – Bethesda, MD

Panelists and Representatives

Karla V. Ballman, Ph.D Mayo Clinic Div of Biostatistics

Rochester, MN 55905 Biostats

Frederick G. Barker, MD Mass. General Hosp Brain Tumor Ctr Boston, MA 02114 Neuro Surgery

Jan C. Buckner, MD Mayo Clinic Div. of Medical Oncology Rochester, MN 55905-001 Med Onc

Ian R. Crocker, MD Emory Clinic Dept of Rad Onc Atlanta, GA 30322-1013 Rad Onc

Barbara Dunn – Patient Rep Ballwin, MO 63021

Howard A. Fine, MD (Co-chair)

National Cancer Institute Ctr. For Cancer Research Bethesda, MD. 20892 Neuro Onc

Henry S. Friedman, MD Duke Medical Ctr Durham, NC 27710

Ped Neuro Onc

Larry E. Kun, MD

St. Jude Children's Research Hosp Dept of Rad Onc Memphis, TN 38105-2729 Rad Onc

Kathleen Lamborn, PhD

Univ of California-San Francisco Dept of Neurosurgery San Francisco, CA 94143-0372 Biostats/Epid

Jay S. Loeffler, MD

Mass General Hospital Dept of Radiation Oncology Boston, MA 02114-2606 Rad Onc

Christina A. Meyers, PhD

MD Anderson Cancer Ctr Neuro-Onc Unit Houston, TX 77230-1402 Neuro Cog Testing

Paolo Paoletti, MD – Industry Rep GlaxoSmithKline Oncology, Medicine Dev Ctr Collegeville, PA 19426 Int Med/Nuclear Med

Roy A. Patchell, MD Univ of Kentucky Medical Ctr Div of Neurosurgery Lexington, KY 40536 Neurosurgeon

Nicholas Patronas, MD

National Institutes of Health Dept of Radiology Warren Grant Magnuson Clinical Ctr Bethesda, MD 20892 Neuro Rad/Imaging

James Provenzale, MD

Duke Univ Med Ctr Dept. of Radiology Durham, NC 27710 Neuro Rad/Imaging

W.K. Alfred Yung, MD

UT MD Anderson Cancer Ctr Dept of Neuro-Onc Houston, TX 77030-4009 Neuro Onc

Brain Tumor End Points Workshop January 20, 2006 Bethesda North Marriott – Bethesda, MD

Panelists and Representatives

FDA Panelists

George Mills, MD

Director Division of Medical Imaging and Hematology Products, Office of Oncology Drug Products,CDER Silver Spring, MD. 20993-0002

Richard Pazdur, MD (Co-chair)

Director Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002

Edwin Rock, MD

Medical Officer Division of Drug Oncology Products, CDER Silver Spring, MD. 20993-0002

Jane Scott, PhD

Endpoint Reviewer Study Endpoints and Label Development Team (SEALD) Office of New Drugs, CDER Silver Spring, MD. 20993-0002

Karen Weiss, MD

Deputy Director Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002

FDA Representatives:

Robert Justice, MD

Acting Director Division of Drug Oncology Products, Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002

Patricia Keegan, MD

Director Division of Biologic Oncology Products, Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002

Khan Li, MD

General Surgery Devices Branch Division of General, Restorative and Neurological Devices Office of Drug Evaluation Center for Devices and Radiological Health Rockville, MD. 20850

David Maybee, MD

Division of Clinical Evaluation & Pharmacology/Toxicology Office of Cell, Tissue, and Gene Therapy Center for Biologics Evaluation and Research (CBER) Rockville, MD. 20850

Mark Rothmann, PhD

Statistical Team Leader for Division of Biologic Oncology Products, Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002

Rajeshwari Sridhara, PhD

Statistical Team Leader for Division of Drug Oncology Products, Office of Oncology Drug Products, CDER Silver Spring, MD. 20993-0002